Cipla, founded in 1935 by Khwaja Abdul Hamied in Mumbai, India, is a leading global pharmaceutical company with a market capitalization of ₹1,27,169 crore as of FY24. It specializes in generics, branded medicines, and active pharmaceutical ingredients (APIs), focusing on therapeutic areas like respiratory, cardiovascular, anti-infectives, and HIV/AIDS. Cipla operates in over 80 countries, with India (39% of revenue), the U.S. (23%), and South Africa as key markets.

Business Model: Initially a generic pharmaceutical company relying on reverse-engineering patented drugs, Cipla shifted post-2005 due to stricter patent laws. It now emphasizes organic growth, selective strategic alliances, and increased exports to Western markets, alongside R&D for niche products. The company operates two segments: Pharmaceuticals (core revenue driver) and New Ventures (consumer healthcare, biosimilars).

Financials: Cipla reported ₹25,774 crore in revenue and ₹4,154 crore in net profit in FY24, with a 25.1% CAGR in profit growth over five years. It maintains low debt (₹559 crore) and a healthy dividend payout of 22%.

Strategic Initiatives: Cipla has expanded through acquisitions (e.g., Ivia Beaute’s cosmetics business for ₹130 crore in 2024) and innovation, launching products like Spirofy (wireless spirometer) and CIPREMI (Remdesivir). Its U.S. subsidiary, Cipla USA, drives growth in complex generics, while Cipla Health Limited strengthens its consumer healthcare portfolio.

Challenges: Cipla faces regulatory hurdles, modest sales growth (9.51% over five years), and competition from global giants. Promoter holding has decreased by 4.43% in recent years, signaling potential vulnerabilities.